Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

309
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
309
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

349
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
349
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

574
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
574
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.0K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.0K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

669
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
669
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapy.

Frontiers in immunology·2026
Same author

Individualized Therapy Guided by Drug Susceptibility Testing for Multidrug-Resistant Tuberculosis.

Open forum infectious diseases·2026
Same author

Acetylator status-guided rapid reintroduction of isoniazid in tuberculosis patients with drug-induced hepatotoxicity.

Journal of clinical tuberculosis and other mycobacterial diseases·2026
Same author

Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing.

Nature communications·2026
Same author

Predictors of Detectable Viral Load among Adolescents with HIV in Low Resource Settings who are Receiving Care in Youth-Friendly Clinics.

AIDS (London, England)·2026
Same author

IgA-Dominant Infection-Related Glomerulonephritis Due to <i>Mycobacterium avium</i>: A Case Report.

Kidney medicine·2026
Same journal

TLR7/8 agonist 3M-052 formulated in micelles induces local type I IFN response and antiviral immunity in zebrafish larvae.

Frontiers in immunology·2026
Same journal

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling.

Frontiers in immunology·2026
Same journal

Gut microbiota transfer from autoimmune dry eye mice imprints stereotypic B cell receptor repertoires in the lacrimal gland and induces disease.

Frontiers in immunology·2026
Same journal

Exosomal microRNAs in colorectal cancer communication networks: implications for metastasis, therapy resistance, and precision medicine.

Frontiers in immunology·2026
Same journal

TMEM160 promotes hepatocellular carcinoma cell proliferation, invasion, and immune evasion by regulating the VEGFA/PI3K/AKT signaling axis.

Frontiers in immunology·2026
Same journal

Nurr1 deficiency orchestrates a coupled liver-gut pathological axis revealed by multi-omics and deep-learning histopathology.

Frontiers in immunology·2026
See all related articles

Related Experiment Video

Updated: Dec 3, 2025

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

81.6K

Perspective for Precision Medicine for Tuberculosis.

Christoph Lange1,2,3,4,5, Rob Aarnoutse6, Dumitru Chesov1,2,3,7

  • 1Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.

Frontiers in Immunology
|October 29, 2020
PubMed
Summary
This summary is machine-generated.

Precision medicine offers a new approach to treating tuberculosis (TB). By analyzing host immunity and Mycobacterium tuberculosis genetics, therapies can be individualized for better outcomes.

Keywords:
endotypesmycobacterial genotypesprecision medicinetailor-made regimentuberculosis

More Related Videos

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
06:07

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

750
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.1K

Related Experiment Videos

Last Updated: Dec 3, 2025

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

81.6K
Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
06:07

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

750
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.1K

Area of Science:

  • Infectious Diseases
  • Genomics
  • Precision Medicine

Background:

  • Tuberculosis (TB) remains a leading global infectious cause of death.
  • Drug-resistant Mycobacterium tuberculosis strains complicate TB elimination efforts.
  • Standardized TB treatment fails to account for individual patient variability.

Purpose of the Study:

  • To propose precision medicine-guided therapies for tuberculosis.
  • To leverage host immunity and M. tuberculosis genetics for treatment decisions.

Main Methods:

  • Utilizing recent scientific discoveries and technological advances.
  • Applying systems biology approaches for personalized treatment.

Main Results:

  • Enabling individualized selection of medicines and host-directed therapies.
  • Facilitating personalized drug dosing and treatment durations.

Conclusions:

  • Precision medicine holds the potential to transform tuberculosis management from standardized to individualized approaches.
  • Advances in systems biology can guide bedside clinical decisions for improved patient outcomes.